Scholarlink

Background <p>Preterm birth is a major adverse neonatal outcome that has been associated with maternal hepatitis B virus carrier status. Co-occurrence of hepatitis B virus carrier status carrier status and gestational diabetes mellitus is associated with an increased risk of preterm birth compared with hepatitis B virus carrier status alone. This study aimed to develop and externally validate a clinically applicable multivariable prediction model incorporating both clinical risk factors and maternal blood biomarkers to estimate preterm birth risk among women with concurrent hepatitis B virus carrier status and gestational diabetes mellitus.</p> Methods <p>A retrospective analysis was performed using clinical data and maternal blood biomarkers from 882 pregnant women with hepatitis B virus carrier status and gestational diabetes mellitus who delivered at Women’s Hospital, in Zhejiang Province, China, from January 2015 to December 2024. Following data preprocessing, participants were randomly allocated to training and validation sets at a 7:3 ratio. Variable selection was performed using the least absolute shrinkage and selection operator (LASSO), and univariate and multivariable logistic regression analyses were subsequently conducted to assess the associations of clinical variables and maternal blood biomarkers with preterm birth in women with concurrent hepatitis B virus carrier status and gestational diabetes mellitus. A nomogram was developed to facilitate clinical application. Model discrimination and calibration were evaluated using receiver operating characteristic curve analysis and calibration plots, respectively, while clinical utility was assessed through decision curve analysis.</p> Results <p>A total of 847 women with hepatitis B virus carrier status and gestational diabetes mellitus were included in this study, of whom 187 (22%) experienced preterm birth. Multivariable logistic regression analysis identified pre-pregnancy body mass index, diastolic blood pressure, systolic blood pressure, alanine aminotransferase, placenta previa, white blood cell count, and maternal blood biomarkers—including total protein, total bile acid, total thyroxine, mode of membrane rupture, and prothrombin time—as independent predictors of preterm birth. These variables were incorporated into a nomogram, which demonstrated good calibration and discrimination. The area under the curve was 0.854 (95% CI: 0.823–0.881) in the training set and 0.754 (95% CI: 0.697–0.806) in the validation set. Decision curve analysis indicated that the nomogram provided favorable clinical utility for predicting preterm birth.</p> Conclusion <p>The model demonstrated good discriminative ability and calibration, enabling accurate prediction of preterm birth risk in women with concurrent hepatitis B virus carrier status and gestational diabetes mellitus.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development and validation of a risk prediction model for preterm birth in women concurrent with Hepatitis B virus carrier status and gestational diabetes mellitus

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月22日

查看全文
  • Zaidi Gui,
  • Xiaoxiao Fan,
  • Tianzi Zang,
  • Hongyan Xu,
  • Qi Wu,
  • Lijun Chen,
  • Jinbing Bai,
  • Yanqun Liu

摘要

Background

Preterm birth is a major adverse neonatal outcome that has been associated with maternal hepatitis B virus carrier status. Co-occurrence of hepatitis B virus carrier status carrier status and gestational diabetes mellitus is associated with an increased risk of preterm birth compared with hepatitis B virus carrier status alone. This study aimed to develop and externally validate a clinically applicable multivariable prediction model incorporating both clinical risk factors and maternal blood biomarkers to estimate preterm birth risk among women with concurrent hepatitis B virus carrier status and gestational diabetes mellitus.

Methods

A retrospective analysis was performed using clinical data and maternal blood biomarkers from 882 pregnant women with hepatitis B virus carrier status and gestational diabetes mellitus who delivered at Women’s Hospital, in Zhejiang Province, China, from January 2015 to December 2024. Following data preprocessing, participants were randomly allocated to training and validation sets at a 7:3 ratio. Variable selection was performed using the least absolute shrinkage and selection operator (LASSO), and univariate and multivariable logistic regression analyses were subsequently conducted to assess the associations of clinical variables and maternal blood biomarkers with preterm birth in women with concurrent hepatitis B virus carrier status and gestational diabetes mellitus. A nomogram was developed to facilitate clinical application. Model discrimination and calibration were evaluated using receiver operating characteristic curve analysis and calibration plots, respectively, while clinical utility was assessed through decision curve analysis.

Results

A total of 847 women with hepatitis B virus carrier status and gestational diabetes mellitus were included in this study, of whom 187 (22%) experienced preterm birth. Multivariable logistic regression analysis identified pre-pregnancy body mass index, diastolic blood pressure, systolic blood pressure, alanine aminotransferase, placenta previa, white blood cell count, and maternal blood biomarkers—including total protein, total bile acid, total thyroxine, mode of membrane rupture, and prothrombin time—as independent predictors of preterm birth. These variables were incorporated into a nomogram, which demonstrated good calibration and discrimination. The area under the curve was 0.854 (95% CI: 0.823–0.881) in the training set and 0.754 (95% CI: 0.697–0.806) in the validation set. Decision curve analysis indicated that the nomogram provided favorable clinical utility for predicting preterm birth.

Conclusion

The model demonstrated good discriminative ability and calibration, enabling accurate prediction of preterm birth risk in women with concurrent hepatitis B virus carrier status and gestational diabetes mellitus.